Ling: High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study [Vitamin D]

High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study

Ling et el., Nutrients, doi:10.3390/nu12123799

Ling, High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with.., et el., Nutrients, doi:10.3390/nu12123799

Dec 2020 Source PDF

Twitter
Facebook

All Studies Meta

80% lower mortality with cholecalciferol booster therapy. Retrospective 986 hospitalized patients in the UK finding that cholecalciferol booster therapy, regardless of baseline serum levels, was associated with a reduced risk of mortality in acute COVID-19 inpatients.

Primary cohort of 444 patients, adjusted mortality odds ratio aOR 0.13, p < 0.001.
Validation cohort of 541 patients, adjusted mortality odds ratio aOR 0.38, p = 0.018.

This is the 14th of 111 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 49 sextillion). 27 studies are RCTs, which show efficacy with p=0.00002.

Important missing comments or errors? Let us know.

risk of death, 79.8% lower, RR 0.20, p < 0.001, treatment 73, control 253, odds ratio converted to relative risk, primary cohort.

risk of death, 55.5% lower, RR 0.44, p = 0.02, treatment 80, control 443, odds ratio converted to relative risk, validation cohort.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Ling et al., 11 Dec 2020, retrospective, United Kingdom, peer-reviewed, 7 authors, dosage 40,000IU weekly, regimen varied with 77% receiving a total of 40,000IU/week.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Vitamin D All

VITAMIN D TREATMENT IS ASSOCIATED WITH REDUCED RISK OF MORTALITY IN PATIENTS WITH COVID-19: A CROSS-SECTIONAL MULTI-CENTRE OBSERVATIONAL STUDY

Ling Mbchb, Eleanor Broad Mbchb, Rebecca Murphy Mbchb, MD Joseph M Pappachan, Satveer Pardesi-Newton Bm, Marie-France Kong, Professor Edward B Jude

Background: The 2019 novel coronavirus disease (Covid-19) worldwide pandemic has posed the most substantial and severe public health issue for several generations, and therapeutic options for it have not yet been optimised. Vitamin D has been proposed in the pharmacological management of Covid-19 by various sources. This study aimed to determine whether Covid-19 disease outcomes were affected by vitamin D status, and to elucidate any predictors of Covid-19 outcomes. Methods: Patients hospitalised with Covid-19 were opportunistically recruited from three different UK hospitals and their data were collected. Logistic regression was used to determine any relationships between vitamin D status and various predictors, including mortality and ventilation, and to determine any relationships between mortality, ventilation, and various predictors. Findings: Vitamin D status was not associated with any outcomes of Covid-19 investigated, following adjustment for age and sex. However, treatment with vitamin D was significantly associated with a reduced risk of death, following adjustment for age and sex (OR adj 0•48, 95% CI 0•32 -0•70, p = 1•79x10 -4 ). This relationship remained significant when also adjusted for baseline vitamin D levels (OR adj 0•47, 95% CI 0•33 -0•70, p = 1•27x10 -4 ). Interpretation: Treatment with vitamin D, regardless of baseline serum vitamin D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with Covid-19. Further work on large population studies needs to be carried out to determine adequate serum levels of vitamin D, as well as multi-dose clinical trials of vitamin D treatment to assess maximum efficacy.

CONFLICT OF INTERESTS The authors have no conflicts of interest.

References

Caccialanza, Laviano, Lobascio, Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol, Nutrition

Calder, Carr, Gombart, Eggersdorfer, Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections, Nutrients

Carter, Baranauskas, Fly, Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic, Obesity (Silver Spring)

Gmmmg, Treatment of Vitamin D Deficiency and Insufficiency in Adults

Grant, Lahore, Mcdonnell, Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths, Nutrients

Hajhashemy, Shahdadian, Ziaei, Saneei, Serum vitamin D levels in relation to abdominal obesity: A systematic review and dose-response meta-analysis of epidemiologic studies, Obes Rev

Hastie, Mackay, Ho, Vitamin D concentrations and COVID-19 infection in UK Biobank, Diabetes Metab Syndr

Iaccarino, Grassi, Borghi, Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension, Hypertension

Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging Clin Exp Res

Jakovac, COVID-19 and vitamin D-Is there a link and an opportunity for intervention?, Am J Physiol Endocrinol Metab

Lovinsky-Desir, Deshpande, De, TABLE 1. SUMMARY STATISTICS OF THE STUDY POPULATION. Number of participants with available data Age (years), J Allergy Clin Immunol

Meltzer, Best, Zhang, Vokes, Arora et al., Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results, JAMA Netw Open

Merzon, Tworowski, Gorohovski, Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study, FEBS J

Munshi, Hussein, Toraih, Vitamin D insufficiency as a potential culprit in critical COVID-19 patients, J Med Virol

Ons, Deaths involving COVID-19

Panagiotou, Tee, Ihsan, Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity, Clin Endocrinol

Pastor-Barriuso, Perez-Gomez, Hernan, SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study

Rhodes, Subramanian, Laird, Kenny, Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity, Aliment Pharmacol Ther

Sacn, Vitamin, Health, None

Silberstein, Vitamin, A simpler alternative to tocilizumab for trial in COVID-19?, Med Hypotheses

Stein, Shane, Vitamin D in organ transplantation, Osteoporos Int

Teymoori-Rad, Shokri, Salimi, Marashi, The interplay between vitamin D and viral infections, Rev Med Virol

Vimaleswaran, Berry, Lu, Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts, PLoS Med

Vitamin, Level, None, median

Who, International Guidelines for Certification and Classification (Coding) of Covid-19 as Cause of Death

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit